Balanitis associated with FOLFIRI chemotherapy
Main Authors: | Goran Micevic, PhD, Sara Harcharik Perkins, MD, Amanda E. Zubek, MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-01-01
|
Series: | JAAD Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352512617302072 |
Similar Items
-
A Case of Metastatic Urachal Carcinoma Treated With FOLFIRI (irinotecan and 5-Fluorouracil/leucovorin) Plus Bevacizumab
by: Tomohiro Kanamaru, et al.
Published: (2015-03-01) -
Metastatic Colorectal Cancer Treated with Herbal Pharmacopuncture during FOLFIRI Chemotherapy: A Case Report
by: Jung-Woo Lee, et al.
Published: (2014-05-01) -
Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis
by: Xu W, et al.
Published: (2016-08-01) -
FOLFIRI Is Tolerable after Subtotal Colectomy – A Patient with Familial Adenomatous Polyposis Who Developed Advanced Rectal Cancer
by: Mitsue Mori, et al.
Published: (2007-12-01) -
FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
by: Caglayan Geredeli, et al.
Published: (2018-03-01)